Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients

Shoaibi et al., medRxiv, doi:10.1101/2020.09.23.20199463

Sep 2020

Source PDF All Studies Meta AnalysisMeta

Retrospective database analysis focused on Famotidine but also showing results for HCQ users, with unadjusted mortality RR 0.85, p<0.001 (13.6% vs. 16.1%). This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.

Important missing comments or errors? Let us know.

risk of death, 15.4% lower, RR 0.85, p < 0.001, treatment 686 of 5,047 (13.6%), control 3,923 of 24,404 (16.1%), NNT 40.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Shoaibi et al., 24 Sep 2020, retrospective, database analysis, USA, preprint, 5 authors.

All Studies Meta Analysis Submit Updates or Corrections

This Paper HCQ All

Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients

PhD Azza Shoaibi, PharmD Stephen Fortin, MS Rachel Weinstein, Jesse A Berlin, PhD Patrick Ryan

doi:10.1101/2020.09.23.20199463

All authors contributed to the conceptualization and design of the study. SF authored the protocol of the study design, AS implemented the statistical analysis, RW, PBR and JB reviewed and approved the study diagnostics and results. AS drafted the manuscript and all coauthors reviewed and contributed to the manuscript writing. .

References

Austin, Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research, Communications in statistics-simulation and computation

Bourinbaiar, Fruhstorfer, The effect of histamine type 2 receptor antagonists on human immunodeficiency virus (HIV) replication: identification of a new class of antiviral agents, Life sciences

Cheung, Hung, Leung, Association between famotidine use and COVID-19 severity in Hong Kong: a territory-wide study, Gastroenterology

Freedberg, Conigliaro, Wang, Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: A propensity score matched retrospective cohort study, Gastroenterology

Howden, Tytgat, The tolerability and safety profile of famotidine, Clinical therapeutics

Janowitz, Gablenz, Pattinson, Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series, Gut

Kritas, Ronconi, Caraffa, Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy, J Biol Regul Homeost Agents

Malone, Tisdall, Smith, COVID-19: Famotidine, histamine, mast cells, and mechanisms

Mather, Seip, Mckay, Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19, Official journal of the American College of Gastroenterology| ACG

Suchard, Schuemie, Krumholz, Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis, The Lancet

Walker, Patrick, Lauer, A tool for assessing the feasibility of comparative effectiveness research, Comp Eff Res

Wu, Liu, Yang, Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods, Acta Pharmaceutica Sinica B

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

@CovidAnalysis

FAQ

Public domain CC0 1.0